A Prospective, Post-Market, Clinical Follow-up Study of the Incompass™ Total Ankle System
Key facts
- Who runs it
- Stryker Trauma and Extremities
- Where
- Charleston, Eugene, Louisville, Morton Grove, and South Bend, United StatesSee the 5 sites
- Trial code
- Status
- Recruiting
- People taking part
- 200 people, planned
- Started
- 6 Feb 2026
- Expected to end
- 1 Sept 2038
- Type of study
- Observational
- Treatments tested
- Total Ankle Replacement
- Record updated
- 24 August 2026
Who can take part
- Age
- 21 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 22 criteriaShow less
Who can take part
- The participant must be willing and able to sign a written approved informed consent form (ICF) approved by Institutional Review Board (IRB) or Ethics Committee (EC)
- Participants must be males or non-pregnant females aged 21 years or older at the time of surgery
- Willing and able to comply with the requirements of the clinical investigation plan (CIP), including attend all required study visits
- The participant must be able to follow instructions and deemed capable of completing clinical investigation questionnaires
- Considered a candidate for total ankle replacement with the Incompass Total Ankle System in accordance with its legally approved Indication for Use (IFU)
Who cannot take part
- Participant is currently enrolled in or plans to enroll in any concurrent drug and/or device clinical investigation that, in the opinion of the Investigator, may confound results
- Participants who have participated previously in this clinical trial and who have been withdrawn
- Participants with a failed previous ankle surgery (e.g., takedown fusion)
- Participants who have documented or suspected sensitivity to the implant materials
- Participant with an ankle condition, as determined by the investigator, to be an inappropriate candidate for total ankle replacement
- Participants with a medical or physical condition that, in the opinion of the Investigator, would preclude safe participation in the clinical investigation
- Participants with any infection at the ankle site or infections at distant sites that could migrate to the ankle, including sepsis and osteomyelitis
- Any mental or neuromuscular disorder that would create an unacceptable risk of failure or complications in postoperative care
- Any participant that meets the definition of a Vulnerable Subject per ISO 14155 Section 3.44
- Participant who is, or will be, inaccessible for follow-up
- Participant is pregnant or intends to become pregnant during the course of the study
- Participants requiring revision total ankle replacement of the ankle being considered for the study
- Participants with compromised vascularity that would inhibit blood supply to the operative site
- Neuropathic arthropathy of the joint
- Insufficient bone stock or bone quality that cannot provide adequate support of the device
- Participants with inadequate neuromuscular status or those having poor skin coverage around the joint, which would make the procedure unjustifiable
- Participant who routinely place excessive loads on their ankle as caused by activity and/or patient weight, per investigator discretion; or
Where in United States
- MUSCCharleston, United StatesContact: Sierra TuftsTaking people
- Slocum Research & Education FoundationEugene, United StatesContact: Hannah CollegeTaking people
- Baptist Health LouisvilleLouisville, United StatesContact: Karin Cryan, BSN RN CCRPTaking people
- Illinois Bone and Joint InstituteMorton Grove, United StatesContact: Vanessa DiazTaking people
- South Bend OrthopedicsSouth Bend, United StatesContact: Derek Yocum, PhDTaking people
About the trial
What the trial wants to find out
The goal of this study is to demonstrate the safety and performance of the Incompass™ Total Ankle System after surgery over the standard follow-up period. The study will measure improvements in patient-reported information related to quality of life and pain following surgery. In order to do this, medical imaging (i.e. X-Rays, CT scans) which have been taken as part of routine care, will be reviewed. Any additional X-Rays conducted during the period of the research will also be reviewed.
Read full original descriptionShow less
The Incompass™ Total Ankle System has been cleared by the Food and Drug Administration (FDA). The products are already in use routinely in ankle replacement surgeries. No part of this study is experimental.
The group in the trial
- Incompass™ Total Ankle System
Primary Total Ankle Replacement using the Incompass™ Total Ankle System
Treatment: Total Ankle Replacement
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Record updated
- 24 August 2026